SEC Form 4 · accession 0001209191-17-009823
BioAmber Inc. · BIOA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Millis
Officer — Chief Technology Officer
Period of report
Feb 9, 2017
Accepted (ET)
Feb 13, 2017 · 7:33 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534287
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-Option (right to buy)F1 | $3.55 | Feb 9, 2017 | A | 60,686 | A | — | Feb 8, 2022 | Common Shares | 60,686 | 60,686 | D |
| Stock-Option (right to buy)F2 | $3.55 | Feb 9, 2017 | A | 50,000 | A | — | Feb 8, 2027 | Common Shares | 50,000 | 50,000 | D |
Explanation of responses
- F1vesting monthly over one (1) year from the grant date
- F2Vesting as follows: twenty-five percent (25%) vesting at the first anniversary date following the grant date, and the remaining seventy-five percent (75%) vesting on a monthly basis over the three (3) following years.